Why Scholar Rock Holding Stock Topped the Market Today

Biotech stock Scholar Rock (NASDAQ: SRRK) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds. This resulted in the stock bumping nearly 3% higher on the day. That handily beat the S&P 500 index, which itself had a good trading session with a 1.7% advance.Scholar Rock targets relatively uncommon disorders that might lack effective treatments.Its current lead drug candidate -- apitegromab, a medicine that preserves muscle mass in patients with two types of spinal muscular atrophy (SMA) -- is under review for approval by both the U.S. Food and Drug Administration and the European Union's European Medicines Agency (EMA). Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool